Almost all patients with polycythemia vera have a gain-of-function mutation in the Janus kinase 2 gene (JAK2) with the resultant constitutively activated JAK/STAT signaling pathway causing the MPN phenotype. Here, JAK2 is linked to myeloproliferative disorder.